NRXCF - NeutriSci International Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0623
+0.0010 (+1.63%)
At close: 11:30AM EDT
Stock chart is not supported by your current browser
Previous Close0.0613
Open0.0700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0623 - 0.0700
52 Week Range0.0390 - 0.1970
Volume18,650
Avg. Volume9,633
Market Cap8.094M
Beta (3Y Monthly)2.66
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire9 hours ago

    NeutriSci Enters Into LOI With Falcon Technologies Inc. dba Eco-Growth Strategies to Manufacture Sublingual CBD Products

    NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products. Upon the successful completion of a due-diligence period, both companies will work towards signing a definitive agreement in early Q2/2019.

  • ACCESSWIRE10 hours ago

    Falcon Technologies aka Eco-Growth Strategies Enters Into LOI With Neutrisci To Manufacture Sublingual CBD Products

    SACRAMENTO, CA / ACCESSWIRE / March 25, 2019 / Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, and Falcon Technologies, Inc. ("Falcon") (FLCN:OTC PINK) are pleased to jointly announce they have entered into a Letter of Intent to create a sublingual CBD tablet. NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products.

  • GlobeNewswire27 days ago

    Neutrisci Announces Product Sales Increase

    Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has received its first order for its sublingual cannabidiol (CBD) tablets. This initial order will result in the Company reporting six figure sales for the current quarter. The quick dissolving, flavoured tablets are manufactured using the Company’s patent pending technology and offer a method to provide the consumer with a measured dose of known CBD product.

  • GlobeNewswire4 months ago

    NeutriSci Announces Exclusive Licensing Agreement for CBD Tablet Manufacturing & Distribution With LaSanta Botanicals Ltd.

    VANCOUVER, British Columbia, Dec. 06, 2018 -- NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer.